Clincosm LogoSign in Get a demo

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Sponsor
Incyte Corporation (Industry)
Overall Status
Approved for marketing
CT.gov ID
NCT05722912
Collaborator
(none)

Study Details

Study Description

Brief Summary

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Incyte Corporation

    Investigators

    • Study Director: Pooja Khandelwal, MD, Children's Hospital Medical Center, Cincinnati

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Incyte Corporation
    ClinicalTrials.gov Identifier:
    NCT05722912
    Other Study ID Numbers:
    • I 18424-22-02
    First Posted:
    Feb 10, 2023
    Last Update Posted:
    Feb 10, 2023
    Last Verified:
    Jan 1, 2023
    Keywords provided by Incyte Corporation
    ruxolitinib
    acute or chronic steroid-refractory GVHD
    hematopoietic stem cell transplantation (allo-HSCT)
    Additional relevant MeSH terms:
    Graft vs Host Disease

    Study Results

    No Results Posted as of Feb 10, 2023